VTRS PDUFA Date: MR-107A-02

Name: MR-107A-02 FDA decision
Start: 2026-12-27
End: 2026-12-27

Updated August 7, 2026·next FDA decision on the calendar

FDA decision (PDUFA) target 2026-12-27 · Viatris Inc. · Pain

All December 2026 PDUFA dates →

The story

MR-107A-02 is under FDA review to treat acute pain.

Full PDUFA calendar ->Every upcoming FDA decision date, by month EXEL . 2026-12-03Same month decision . XL092 with atezolizumab ANAB . 2026-12-12Same month decision . Imsidolimab (ANB019)VNDA . 2026-12-12Same month decision . Imsidolimab (ANB019)

Plain-English summary compiled by pdufa.bio from public FDA, SEC and company sources. Informational only - not investment advice.

VTRS run-up into the PDUFA (last ~120 days)

Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-27

Drug / candidateMR-107A-02

IndicationPain

CompanyViatris Inc.

Market-cap tierLarge

Cohort decision-day move (history)±1% median

ClinicalTrials.govNCT06215859

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

See the full 2026 PDUFA calendar →

FAQ

When is the VTRS PDUFA date?

The FDA PDUFA target date for VTRS (Viatris Inc.) is 2026-12-27 for MR-107A-02. Dates are company/FDA-sourced and can slip. Verify against primary filings.

What is VTRS's drug MR-107A-02?

MR-107A-02 is Viatris Inc.'s candidate under FDA review for Pain.

What typically happens to a large-cap stock into a PDUFA date?

Historically, large-cap names had a median decision-day move around ±1% (763-PDUFA cohort, 2024-26). This is historical context by market-cap tier, not a prediction for this drug.

Decision-day move · large-cap cohortn=790 · median +0.0% · 50% up

Distribution of next-day % moves after the FDA decision for large-cap PDUFAs (2020–26). Red = down, green = up, blue = flat (±3%). Historical dispersion, not a forecast.